|Bid||56.00 x 800|
|Ask||56.04 x 800|
|Day's Range||55.50 - 56.73|
|52 Week Range||38.95 - 99.36|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.67|
Nick Leschly has been the CEO of bluebird bio, Inc. (NASDAQ:BLUE) since 2010, and this article will examine the...
The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.
bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD.